 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Nov 5 Calls Today's Calls |
| Call Details | |||
| Abraxis BioScience, Inc. Earnings Conference Call (Q3 2009) Thu, Nov 5, 2009, 11:30 am Eastern
| |||
| About Abraxis BioScience, Inc. (NasdaqGS:ABII) | |||
| Abraxis BioScience, Inc., a biotechnology company, engages in the discovery, development, and delivery of next-generation therapeutics and core technologies that offer treatments for cancer and other critical illnesses. The company’s product pipeline includes clinical oncology and cardiovascular product candidates in various stages of testing and development. Its principal product includes Abraxane, a nanoparticle chemotherapeutic compound that is based on its proprietary tumor targeting nab technology platform for the treatment of metastatic breast cancer. Abraxis BioScience’s other clinical product candidates include ABI-008, a solvent-free, Tween-free nanometer-sized form of docetaxel for the treatment of hormone refractory prostate cancer and metastatic breast cancer; ABI-009, a nab-rapamycin mTOR inhibitor for the treatment of solid tumors; ABI-010, a polyketide inhibitor of heat shock protein 90 for the treatment of multiple cancers; ABI-011, a thiocolchicine dimer for microtubule destabilization and the disruption of topoisomerase-1 activity; and Coroxane, a nanometer-sized paclitaxel for coronary restenosis and peripheral artery restenosis. It has strategic relationships with Taiho Pharmaceutical Co., Ltd.; Biocon Limited; and ProMetic Life Sciences Inc. Abraxis BioScience also has licensing agreements with Green Cross Corporation and University of Southern California. The company was formerly known as New Abraxis, Inc. and changed its name to Abraxis Bioscience, Inc. in November 2007. Abraxis BioScience is based in Los Angeles, California. | |||
More Info: | |||
